Allergen immunotherapy subcutaneous - Stallergenes Greer plc
Alternative Names: AlustalLatest Information Update: 01 Jul 2021
At a glance
- Originator Stallergenes Greer plc
- Class Allergens; Allergy immunotherapies; Anti-infectives; Anti-inflammatories; Antiallergics; Eye disorder therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Conjunctivitis; Perennial allergic rhinitis; Rhinoconjunctivitis; Seasonal allergic rhinitis
Most Recent Events
- 24 Jun 2021 Launched for Conjunctivitis (In adolescents, In children, In adults) in Italy and Spain (SC)
- 24 Jun 2021 Launched for Perennial allergic rhinitis (In adolescents, In children, In adults) in Italy and Spain (SC)
- 24 Jun 2021 Launched for Rhinoconjunctivitis (In adolescents, In children, In adults) in Italy and Spain (SC)